2023-12-31 13:06:05
Home Local News
December 31, 2023
Watan Al-Youm: The General Food and Drug Administration has developed foundations to simplify approval procedures for conducting pharmaceutical studies for value-added medicines with the aim of enhancing drug security and providing new types and various alternatives to safe and effective medicines to citizens at competitive prices, in order to achieve the lofty royal visions in achieving drug security and in response to the royal directives for modernization. The economic.
The Director General of the Foundation, Nizar Mhaidat, stated in a press statement that the newly developed principles, which were circulated to all concerned parties, include several criteria for granting pharmaceutical studies for value-added drugs priority in terms of evaluation and approval by the Foundation’s Pharmaceutical Studies Committee, especially studies submitted for drugs that It carries new added value and high-quality, high-priced medicines, such as medicines for cancer and rare diseases for which there are not many treatment options, while maintaining the application of the highest levels of good clinical and laboratory practices in a way that guarantees the safety and rights of participants in the studies and proves the effectiveness and safety of local and international medicines associated with the pharmacological study before authorizing them for circulation.
Mhaidat added that this specific measure came within the framework of a package of measures taken by the institution to ensure the simplification of approval procedures for conducting pharmaceutical studies in the centers and agencies related to conducting pharmaceutical studies in the Kingdom, especially pharmaceutical studies for value-added medicines, in a way that contributes to enhancing pharmaceutical exports and attracting more visitors. Investments in this pioneering sector that contributes to supporting economic growth.
It is noteworthy that Jordan is the first Arab country to enact a special law for pharmaceutical studies since 2001 with the aim of organizing their conduct according to the international reference principles in this field, including the foundations of good clinical practice (GCP), in view of the importance of these pharmaceutical studies as a basic stage in the drug development process and as a requirement for registering alternatives.
#Creating #foundations #simplify #approval #procedures #conducting #drug #studies #Watan #News